Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the ‘SENDO experience’

Dose-response relationship in phase I clinical trials: A European Drug Development Network (EDDN) collaboration study.

(2017) P. A. Cassier et al.   JOURNAL OF CLINICAL ONCOLOGY

High Incidence of Thromboembolic Events in Patients Treated With Cisplatin-Based Chemotherapy: A Large Retrospective Analysis

(2011) Russell A. Moore et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: The M. D. Anderson Cancer Center experience

(2009) Sushma Vemulapalli et al.   AMERICAN JOURNAL OF HEMATOLOGY

The Incidence and Risk of Venous Thromboembolism Associated With Cancer and Nonsurgical Cancer Treatment

(2009) Anna Falanga   CANCER INVESTIGATION

Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study

(2009) Giancarlo Agnelli et al.   LANCET ONCOLOGY

High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)

(2008) C. Ay et al.   BLOOD

Development and validation of a predictive model for chemotherapy-associated thrombosis

(2008) A. A. Khorana et al.   BLOOD

Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: The ‘GISCAD-alternating schedule’ study findings

(2008) Mario Mandalà et al.   EUROPEAN JOURNAL OF CANCER